CPAN Inhibitors
Chemical inhibitors of CPAN target its function by interfering with the regulatory mechanisms of the cell cycle, primarily through the inhibition of cyclin-dependent kinases (CDKs), which are essential for cell cycle progression. Alsterpaullone, Roscovitine, and Kenpaullone serve as potent inhibitors of CDKs, which CPAN relies on for its role in cellular processes. Alsterpaullone, in particular, has been identified to obstruct CDK activity, leading to a disruption of the cell cycle. This disruption can cause an indirect inhibition of CPAN since its activity is dependent on the proper progression of the cell cycle. Similarly, Roscovitine's ability to hinder CDKs can lead to the inhibition of CPAN by preventing the cell cycle from advancing as required for CPAN's function. Kenpaullone adds to this effect by not only inhibiting CDKs but also glycogen synthase kinase 3 (GSK-3), which is involved in additional signaling pathways that affect CPAN's role in the cell.
Moreover, compounds like Indirubin-3'-monoxime, Purvalanol A, and Flavopiridol further exemplify the strategy of inhibiting CDKs to regulate CPAN activity. Indirubin-3'-monoxime targets CDKs and GSK-3, similar to Kenpaullone, altering the phosphorylation state of proteins associated with CPAN's regulation. Purvalanol A, with its selectivity towards CDKs, disrupts the cycle and, consequently, CPAN's associated mechanisms. Flavopiridol also arrests the cell cycle by inhibiting CDKs, thereby affecting CPAN's function, which is contingent on the cell cycle's integrity. Other inhibitors such as Olomoucine, Butyrolactone I, AT7519, Dinaciclib, AZD5438, and RGB-286638 contribute to the collective impact on CPAN by their varied yet convergent pathways of CDK inhibition, each leading to an alteration in cell cycle dynamics, which in turn, can regulate CPAN activity indirectly through these disrupted cellular processes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). Since CPAN is involved in cellular processes that may be regulated by CDK activity, inhibition of CDKs by Alsterpaullone leads to disruption of the cell cycle, which can result in functional inhibition of CPAN due to its dependence on cell cycle progression. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine serves as another CDK inhibitor which can hinder cell cycle progression. As CPAN is reliant on proper cell cycle control for its function, disruption of this process by Roscovitine can cause downstream inhibition of CPAN activity. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone, similar to Alsterpaullone, inhibits CDKs and glycogen synthase kinase 3 (GSK-3). By inhibiting these kinases, Kenpaullone can disrupt signaling pathways that are essential for CPAN function, resulting in its inhibition. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $79.00 $321.00 $671.00 | 1 | |
Indirubin-3'-monoxime is an inhibitor of CDKs and GSK-3. The inhibition of these kinases can affect the phosphorylation state of proteins that regulate the cell cycle and other cellular functions, thereby indirectly inhibiting CPAN by impeding the processes it is involved in. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $72.00 $297.00 | 4 | |
Purvalanol A is a selective inhibitor of CDKs. By inhibiting CDKs, this compound can disrupt the cell cycle and other regulatory mechanisms that CPAN requires for its functional role, leading to its inhibition. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol inhibits CDKs, leading to cell cycle arrest. Since CPAN's function is closely tied to cell cycle phases, the inhibition of CDKs and subsequent cell cycle arrest can inhibit CPAN function. | ||||||
Olomoucine | 101622-51-9 | sc-3509 sc-3509A | 5 mg 25 mg | $72.00 $274.00 | 12 | |
Olomoucine is a CDK inhibitor that can interfere with cell cycle progression. Inhibition of cell cycle-related kinases can indirectly inhibit CPAN by preventing the cellular conditions necessary for its activity. | ||||||
Butyrolactone I | 87414-49-1 | sc-201533 sc-201533A | 200 µg 1 mg | $122.00 $514.00 | 1 | |
Butyrolactone I is a selective inhibitor of CDK2. By preventing CDK2 activity, it can arrest the cell cycle, which in turn can inhibit CPAN function as CPAN is implicated in cell cycle-dependent processes. | ||||||
AT7519 | 844442-38-2 | sc-364416 sc-364416A sc-364416B sc-364416C | 5 mg 10 mg 100 mg 1 g | $291.00 $341.00 $1046.00 $3126.00 | 1 | |
AT7519 inhibits multiple CDKs and disrupts the progression of the cell cycle. As CPAN functions are reliant on cell cycle progression, inhibition of these kinases by AT7519 can lead to the functional inhibition of CPAN. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $247.00 $888.00 | 1 | |
Dinaciclib is a potent CDK inhibitor. It disrupts various CDK-mediated processes, leading to cell cycle arrest. This arrest can functionally inhibit CPAN by hindering the cell cycle-dependent processes it is involved in. | ||||||